Search results
Showing 556 to 570 of 690 results for innovative
ViewSite Brain Access System (VBAS) for the surgical management of deep brain lesions (MIB295)
NICE has developed a medtech innovation briefing (MIB) on ViewSite Brain Access System (VBAS) for the surgical management of deep brain lesions .
NICE has developed a medtech innovation briefing (MIB) on MiraQ cardiac TTFM with high-frequency probe for assessing graft flow during coronary artery bypass graft surgery .
NICE has developed a medtech innovation briefing (MIB) on Bindex for investigating suspected osteoporosis .
NICE has developed a medtech innovation briefing (MIB) on microINR for anticoagulation therapy .
Alere Afinion CRP for C-reactive protein testing in primary care (MIB81)
NICE has developed a medtech innovation briefing (MIB) on the Alere Afinion CRP for C-reactive protein testing in primary care
NICE has developed a medtech innovation briefing (MIB) on TopClosure Tension Relief System for wound closure .
Ambu aScope 4 Broncho for routine diagnostic and therapeutic bronchoscopy (MIB314)
NICE has developed a medtech innovation briefing (MIB) on Ambu aScope 4 Broncho for routine diagnostic and therapeutic bronchoscopy .
Evidence-based recommendations on baricitinib (Olumiant) for treating severe alopecia areata in adults.
Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (TA424)
Evidence-based recommendations on pertuzumab (Perjeta) for treating HER2-positive breast cancer that is locally advanced, inflammatory, or early-stage with a high risk of recurrence, in adults.
Evidence-based recommendations on carfilzomib (Kyprolis) for previously treated multiple myeloma in adults.
Nalmefene for reducing alcohol consumption in people with alcohol dependence (TA325)
Evidence-based recommendations on nalmefene (Selincro) for reducing alcohol consumption in adults with alcohol dependence.
Workplace health: long-term sickness absence and capability to work (NG146)
This guideline covers how to help people return to work after long-term sickness absence, reduce recurring sickness absence, and help prevent people moving from short-term to long-term sickness absence.
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia (TA663)
Evidence-based recommendations on venetoclax (Venclyxto) with obinutuzumab for untreated chronic lymphocytic leukaemia in adults.
Zanubrutinib for treating chronic lymphocytic leukaemia (TA931)
Evidence-based recommendations on zanubrutinib (Brukinsa) for treating chronic lymphocytic leukaemia in adults.
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (TA540)
Evidence-based recommendations on pembrolizumab (Keytruda) for treating relapsed or refractory classical Hodgkin lymphoma in adults.